Semnur Pharmaceuticals, Inc. · OTC:SMNR

Semnur Pharmaceuticals — Investor Presentation (August 2024)

31 slides from Semnur Pharmaceuticals's investor presentation, August 2024

  1. Slide 1: Semnur Pharmaceuticals

    Semnur Pharmaceuticals 960 San Antonio Rd, Palo Alto CA 94303 Wholly Owned Subsidiary of Scilex Holding Company (NASDAQ: SCLX)

  2. Slide 2: Safe Harbor Statements Forward-Looking Statements

    Safe Harbor Statements Forward-Looking Statements Certain statements contained in this corporate presentation (this “Presentation”), along with certain statements that may be made by management of Scilex Holding Company (together with its subsidiaries, “Scilex”) orally in presenting this material, a

  3. Slide 3: History of Semnur Pharmaceuticals

    History of Semnur Pharmaceuticals • Semnur founded in 2013 with Series A $30MM 1 investment from Canaan Partners, Frazier Healthcare, and Vivo Capital. • On March 22, 2019, Scilex Pharmaceuticals Inc. has closed a transaction to merge with Semnur Pharmaceuticals, Inc. to form a new company, Scilex H

  4. Slide 4: Semnur Pharmaceuticals Merger with Denali Acquisition Corporation

    Semnur Pharmaceuticals Merger with Denali Acquisition Corporation • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX), and Denali 1 Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination. • On July 2,

  5. Slide 5: SEMDEXA (SP-102) On-Track to be the First Product Approved to Treat Sciatica

    SEMDEXA (SP-102) On-Track to be the First Product Approved to Treat Sciatica SP-102 is a preservative free, surfactant free and particulate free viscous gel formulation of dexamethasone for sciatica (lumbosacral radicular pain). Extended local effect provides durable pain relief and significant impr

  6. Slide 6: SP-102 Market Opportunity

    SP-102 Market Opportunity Developing SP-102 as a non-opioid injectable therapeutic for low back pain Novel viscous gel formulation, optimized for epidural injection Novel biocompatible excipient enables extended local effect On track to be the first and only FDA-approved epidural steroid product Cur

  7. Slide 7: SP-102 Differentiated Product Profile & Positioning

    SP-102 Differentiated Product Profile & Positioning Depo-Medrol Dexameth- Kenalog Celestone Important Treatment Attributes SP-102 (triamcinolone) (methylprednis- asone (betamethasone) 1 olone) FDA-approved for lumbosacral ✓ – – – – radicular pain Robust clinical data demonstrating safety – ✓ – – – a

  8. Slide 8: Reimbursement – J code Timelines for New Products

    SP-102 Reimbursement – J code Timelines for New Products • SP-102 has strong value proposition as the first proven and indicated preservative-free epidural injection for lumbar radiculopathy • Strong case for economic benefits associated with use of epidural steroid injections to defer more complica

  9. Slide 9: Epidural Steroid Injections (ESI) for Chronic Back Pain

    Epidural Steroid Injections (ESI) for Chronic Back Pain One of the Most Common Medical Procedures / Top Pain Procedures Strong Growth Rate, Evidenced by Medicare Procedure Volumes (MM) Medicare Overall ESI Injection Volume1 1▪ ESIs widely reimbursed as procedure to delay or avoid back surgery 2▪ Tra

  10. Slide 10: Syneos Health Forecast (Base Case)

    Syneos Health Forecast (Base Case) SP-102 is projected to earn revenues of $1,651 million at peak uptake in Year 5 in lumbar radiculopathy patients, across all specialists (Anesthesiologists, PM&R Specialist, and IPM Specialists) at a launch price of $400. 10

  11. Slide 11: SEMDEXA – Broad Potential for Life Cycle Management

    SEMDEXA – Broad Potential for Life Cycle Management 1 Physicians indicated there is potential opportunity for spontaneous use of SEMDEXA outside of lumbar radiculopathy which could represent an additional upside of ~50-200%* over LR 2 Additional Uses ▪ Carpel Tunnel ▪ Hip and Knee Replacements ▪ Tri

  12. Slide 12: Syneos Health Forecast (Best Case)

    Syneos Health Forecast (Best Case) SP-102 is projected to earn peak revenues of $3,685 million from both lumbar radiculopathy and non-lumbar radiculopathy patients from all specialists at a launch price of $400. 12

  13. Slide 13: Lumbosacral Radicular Pain (Sciatica)

    Lumbosacral Radicular Pain (Sciatica) Lifetime incidence 13 - 40% Rarely diagnosed before the age of 20, peaks in the 50s and declines thereafter ~ 90% of cases caused by a herniated disc with nerve root compression Confidential, not for distribution 13

  14. Slide 14: Summary of Select Systematic Reviews and Meta-analyses

    Summary of Select Systematic Reviews and Meta-analyses: Meta-Analyses and Systemic Reviews Type Publication Intervention Outcomes Improvement Improvement Surgery in Pain in Function Avoidance RCT Carette 1997 ESI vs Placebo Meta-analysis Chou 2015 ESI Meta-analysis Bhatia 2016 ESI +/- Local Anesthet

  15. Slide 15: Fungal Meningitis Outbreaks

    Fungal Meningitis Outbreaks Meningitis outbreak caused by compound pharmacy produced steroids for epidural injections, contaminated with Aspergillus fumigatus, infected more than 800 people across 20 states in 2012, 64 of whom died. By Kurt Eichenwald / April 16, 2015 http://www.newsweek.com/2015/04

  16. Slide 16: History of Serious Spinal Adverse Events Associated with ESIs

    History of Serious Spinal Adverse Events Associated with ESIs: Resulting FDA Warning in All Injectable Corticosteroid Product Labels 1997-2014 90 serious (including fatal) neurological events following ESIs reported to FAERS 2014 FDA required warning for all injectable corticosteroid product labels

  17. Slide 17: SP-102 (SEMDEXA) Toxicology GLP Studies (dogs and pigs)

    SP-102 (SEMDEXA) Toxicology GLP Studies (dogs and pigs) No drug-related effects on any parameter: ECG, Clin obs, BW, Neurology, Clinical pathology & chemistry. Histopathology: no drug-induced adverse effects, including special stains Dose dependent PK, both plasma & CSF, cleared by 24 h. Cortisol su

  18. Slide 18: SP-102 (SEMDEXA) Pharmacokinetic Bridging Trial

    SP-102 (SEMDEXA) Pharmacokinetic Bridging Trial Epidural SP-102 injection was well tolerated Not associated with greater systemic dexamethasone exposure than IV dexamethasone at the same dose 10 mg (Reference Listed Drug) Equivalent AUC Lower mean plasma Cmax (~ 50% lower) Both treatments had simila

  19. Slide 19: SP-102 (SEMDEXA) Phase 2: Repeat Dose PD trial

    SP-102 (SEMDEXA) Phase 2: Repeat Dose PD trial The repeat injection had similar effects on cortisol suppression time (~5 days), glucose levels and WBC count. No cumulative effect. There were no SAEs or discontinuations due to adverse events. SP-102 provided prolonged pain relief, with preliminary ev

  20. Slide 20: SP-102 (SEMDEXA) C.L.E.A.R. Trial Schema

    SP-102 (SEMDEXA) C.L.E.A.R. Trial Schema Inclusion Radicular leg pain episode (4-9 NPRS) MRI confirmed No prior ESI (epidural steroid injection) No opioids or NSAIDs Stable, >4 avg NPRS pain in 21d screening Primary Endpoint Secondaries (W2, W4, W8, W12) Change in mean leg pain Leg pain (NPRS, avg &

  21. Slide 21: SP-102 (SEMDEXA) C.L.E.A.R. Trial Met Primary Endpoint

    SP-102 (SEMDEXA) C.L.E.A.R. Trial Met Primary Endpoint (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) Primary Endpoint (mITT) Largest prospective, double-blind, randomized study in Sciatica (n=401) Change in Average Daily Pain in Affected Leg 0,5 The trial met primary, key secondary and

  22. Slide 22: SP-102 (SEMDEXA) C.L.E.A.R. Trial Secondary Endpoints (ITT)

    SP-102 (SEMDEXA) C.L.E.A.R. Trial Secondary Endpoints (ITT) Key Secondary Endpoint The Oswestry Disability Index (ODI) - gold standard for measuring degree of disability and estimating quality of life, contains 10 topics concerning intensity of pain, lifting, ability to care for oneself, ability to

  23. Slide 23: SP-102 (SEMDEXA) C.L.E.A.R. Trial – Effect Duration and Safety

    SP-102 (SEMDEXA) C.L.E.A.R. Trial – Effect Duration and Safety SP-102 Time to Repeat Injection (Return of Moderate-Severe Pain) Month 1 Month 2 Month 3 Month 4 Month 5 Primary Endpoint Allowance for Open-Label Repeat Injection of SP-102 SP-102 showed continued reduction of pain beyond one month, and

  24. Slide 24: SP-102 (SEMDEXA) C.L.E.A.R. Safety Summary

    SP-102 (SEMDEXA) C.L.E.A.R. Safety Summary No AEs of special interest (paraplegia, hematoma, infection) No SAEs related to drug or injection procedure No meaningful differences in physical examinations, vital signs, or laboratory parameters between treatment groups Confidential, not for distribution

  25. Slide 25: SP-102 Regulatory Discussion(s) to Date

    SP-102 Regulatory Discussion(s) to Date 1 Toxicology program complete 2 Pharmacokinetic bridge established to Reference Listed Drug 3 Phase II, additional PK / PD / Safety of repeat injection trial completed 4 CLEAR Trial completed 5 NDA 505(b)(2) application confirmed 6 25

  26. Slide 26: SP-102 Milestones

    SP-102 Milestones 1 CLEAR-2 trial from Q4-2024 to Q3-2026 • CLEAR-2 Trial: Randomized, Active-controlled, Double-Blind, Multi-Center Trial in Subjects with Lumbosacral Radicular Pain (Sciatica). o Endpoints: Non-Inferiority on leg pain over 4 weeks, Superiority on time to repeat injection, treatment

  27. Slide 27: Semnur Pharmaceuticals Management Team

    Semnur Pharmaceuticals Management Team Jaisim Shah Suketu Desai Dmitri Lissin, MD Henry Ji, PhD Chief Technology Officer Stephen Ma Chief Executive & President Chief Medical Officer Executive Chairman Chief Financial Officer ▪ 25+ years of management ▪ 25+ years in manufacturing / CMC, ▪ 20+ years i

  28. Slide 28: Regulatory & Clinical/Non-Clinical Research & Development

    Regulatory & Clinical/Non-Clinical Research & Development Chief Medical Officer & Senior Vice President, Clin Dev/Med Dmitri Lissin Executive Coordinator & Office/Facilities Manager Ja cob Hee Executive Director, R&D Consultant Clinical Data Freelance Senior Director, Clinical Director, Clinical Sta

  29. Slide 29: Chemistry, Manufacturing & Quality Assurance

    Chemistry, Manufacturing & Quality Assurance Chief Technology Officer & Senior Vice President, Chemistry/Manufacturing/Regulatory Affairs Suketu Desai Executive Coordinator & Office/Facilities Manager Ja cob Hee Senior Director, Director, Business Quality Assurance Director, Regulatory Director, Man

  30. Slide 30: Finance

    Finance Chief Financial Officer &Senior Vice President, Finance Stephen Ma Executive Coordinator & Office/Facilities Manager Ja cob Hee Director, Finance Senior Director Linda Wu Director, IT Corporate Controller Executive Director, Senior Director, Price, Contracts & Ben Emirian Head of Internal Co

  31. Slide 31: Administrative Operations & Human Resources

    Administrative Operations & Human Resources Executive Director of Administrative Operations Gigi DeGuzman Executive Coordinator Office/Facilities Manager Jacob Hee HR Specialist, Manager, Administrative Manager Operations & HR Isabel Quinn Mounika Ravula 31

Semnur Pharmaceuticals — Investor Presentation (August 2024) on 6ix